ThePackage leaflet: Information for the patient . Among its multifaceted functions is the ability to connect the absorption of nutrients from the gastrointestinal tract with pancreatic hormone secretion. Indications and Usage. You can help by reporting any side effects you may get. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with semaglutide. semaglutide 0. Patients should be advised to read the instruction for use included in the package leaflet carefully before administering the medicinal product. It works by helping the pancreas to release the right amount of insulin when blood sugar levels are high. 7 mg and 2. Semaglutide injection Limited availability. Insulin. Wegovy with Next-Day Delivery. 5 mg solution for injection in pre-filled pen. Why am I using Saxenda®? Saxenda® contains the active ingredient liraglutide. 05 L/h. If you have any questions or are worried about anything, please speak to your Community Diabetes Nurse, GP, or phone 111. Keep all appointments with your doctor and the laboratory. A 12-week long trial was carried out on 415 subjects to find the optimal dose of semaglutide. Counsel patients regarding5. Important Safety Information for SEMGLEE (insulin glargine-yfgn injection) pen. 5 mg, 1 mg, 1. 5 mg, 1 mg, or 2 mg For adult patients with type 2 diabetes (T2D), treated with diet and exercise to improve glycemic control, and to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with T2D and established cardiovascular disease. 9–16. g. a Applies to eligible commercially insured patients. the proportion of patients with. Counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors (e. along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes. Changes to the PIL after your medicine was packed may mean. Weight Management Study in Pediatric Patients Aged 12 Years and Older with Obesity 14. This drug comes with an extra patient fact sheet called a Medication Guide. Semaglutide is a potent glucagon-like peptide 1 receptor agonist for the management of type 2 diabetes mellitus. INTRODUCTION. While GLP-1RAs effectively improve glycemic control and cause weight loss, potential safety concerns have arisen over the. 7 mg and 2. Trade Name Ozempic. The clearance of semaglutide in patients with overweight (BMI ≥27 kg/m 2 to <30 kg/m 2) or obesity (BMI ≥ 30 kg/m 2) was approximately 0. Patients should be advised to read the instruction for use included in the package leaflet carefully before administering the medicinal product. Risk of Thyroid C-Cell Tumors: Patients should be referred to an. 3 Cardiovascular Outcomes Trial of Semaglutide 0. See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Patients with a history of diabetic retinopathy should beFor practical information about using Wegovy, patients should read the Patient Information Leaflet (PIL) or contact their doctor or pharmacist. Swallow the tablets whole, do not cut, crush, or chew. Abstract. 1-844-TLR-MADE; 1 (859) 887 0013; support@tailormadecompounding. 0 mg) or oral semaglutide (14 mg) given as monotherapy were able to reduce HbA 1c by. How to store Saxenda® 6. Semaglutide. A greater number of patients in the semaglutide group achieved an HbA1c <7% compared with the liraglutide and placebo groups. There may be new information. 17. (page 13-16) How to store Ozempic® (page 17-18) Contents of the pack and other information (page 19) Instructions on how to use Ozempic® 0. Below is a text only representation of the Patient Information Leaflet (ePIL). 25 mg, 0. Some drugs may have another patient information leaflet. See inside for more information. Last updated on emc: 14 Aug. According to the patient information leaflet, this only affects around 1 in 100, so roughly 1% of Semaglutide users are likely to experience acute pancreatitis. Research has found that when people stop using semaglutide medications like Ozempic and Wegovy, weight rebound occurs. A. Wegovy ® (semaglutide) injection 2. All of the instructions that you need to inject Semaglutide are included in the patient information leaflet. 3. This medicine is subject to additional monitoring. Changes to the PIL after your medicine was packed may mean. 05 L/h. 4 mg once a week. 4 mg is an injectable prescription medicine used for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also. Includes indications, proper use, special instructions, precautions, and possible side effects. How and when to take it. 55], p=0. What Saxenda® is and what it is used forINS186 PDF leaflet updated. Use in elderly • Wegovy™ is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy™. Context Efficacy and safety of once-weekly semaglutide in type 2 diabetes were established in the phase 3 SUSTAIN trials, which included patients across the continuum of type 2 diabetes care. 5 Acute Gallbladder Disease 17. 53,54. Ozempic ® (semaglutide) injection 0. uk | +44 (0)020 7383 0266More participants in the semaglutide group than in the placebo group achieved weight loss ≥5% from baseline at week 104 (77. 9% for placebo group. † Regulations require you to enter your drug identification number (DIN) to access content that is intended only for patients who have been prescribed Ozempic ® . 00 pm on weekdays and bank holidays For more information on diabetes, visit our website If you are feeling unwell or in case of an emergency, please contact your doctor. 4 mg. 4 mg once-weekly dosage, the maintenance dosage may be reduced to 1. Indications and Usage. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with semaglutide. Discontinue promptly if pancreatitis is suspected. Follow all instructions closely. 5. Current guidelines emphasize the need for a patient‐centric approach in type 2 diabetes (T2D), with treatment individualized to a patient's clinical characteristics. Semaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. RYBELSUS® (semaglutide) is a prescription medicine used along with diet and exercise to improve blood sugar in adults with type 2 diabetes. Use in renal impairment Experience with the use of semaglutide in patients with severe (CrCL < 30 mL/min) renal impairment is limited. Objective SURE Germany evaluated once-weekly semaglutide in a real-world. c. semaglutide and is authorised for the treatment of type 2 diabetes. Semaglutide (Ozempic®) should be injected once weekly at any time of the day, with or. Dulaglutide (~ 63,000 Da) is derived from two modified GLP-1 molecules attached to an Fc fragment of immunoglobulin G and has a half-life of ~ 5 days []. 8%). 0001). The development of semaglutide is an example of our commitment to innovation for people living with chronic dis-eases. solution for injection in pre-filled pen. along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes. Keep taking it unless your care team tells you to stop. patients at risk of running out of Ozempic® are safely switched to another glucagon-like peptide-1 receptor agonist or other suitable alternatives based on your clinical judgement) • An alternative form of semaglutide; Rybelsus (oral semaglutide) is currently available in. Check the Ozempic® flow with each new pen. (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined (5. • Suicidal Behavior and Ideation: Monitor for depression or suicidal thoughts. (semaglutide) is approved and licensed. It works slowly around the day to make your child feel less hungry. After 4 weeks the dose should be increased to 0. The product information document provides detailed information on the benefits and risks of Wegovy, as well as the dosage, administration and precautions. 4 mg weekly) to achieve maximum weight loss. 7 In the phase III Semaglutide Treatment. Patient leaflet and Counselling check list Semaglutide —Ozempic® At your appointment today we have agreed to start treatment with a WEEKLY injectable medicine to help manage your type 2 diabetes. Experience with the use of semaglutide in patients with severe renal impairment is limited. Dermatology Referral Guidelines. 1. For a comprehensive list of possible side effects, please refer to section 4 of the patient information leaflet. 1). Rybelsus® contains the active substance semaglutide. For further information call emc accessibility on 0800 198 5000 . This drug comes with an extra patient fact sheet called a Medication Guide. Ozempic ® (semaglutide) injection 0. 7 mg and 2. 4 mg weekly injection of semaglutide plus lifestyle intervention in 1,961 patients with-PATIENT & CAREGIVER EDUCATION Semaglutide This information from Lexicomp explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and. Semaglutide injection (Ozempic) is also used to reduce the risk of a stroke, heart attack, or death in adults who have type 2 diabetes along with heart and blood vessel disease. Semaglutide is a GLP-1 receptor agonist recently approved by the FDA for weight management at a dose of 2. Willan House, 4 Fitzroy Square, London, W1T 5HQ | admin@bad. • to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes withThe complete list of side effects is available in the patient information leaflet, which you should read before you start to take Semaglutide. The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. Ozempic® (semaglutide) injection 0. 3 Risk of Thyroid C-cell Tumors 17. 4 mg. 1,20,21,27 In the. This can help with blood glucose levels. Glucagon-like peptide 1 (GLP-1) is an incretin hormone that is released during a meal. 1. Wegovy™ (semaglutide) injection 2. Pen cap. For chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with a BMI ≥30 kg/m 2 (obesity), or ≥27 kg/m 2 (overweight) in the presence of a weight-related comorbidity, and for pediatric patients aged 12 years and older with an initial BMI at ≥95. , prediabetes, hypertension, and obstructive sleep apnea). Inform patients that semaglutide causes thyroid C-cell tumors in rodents and that the human relevance of this finding has not been determined. Some drugs may have another patient information leaflet. Maximum savings is $150 for a 1-month supply, $300 for a 2-month supply, and $450 for 3-month supply. 55%) after 30 weeks. A Medication Guide is patient labeling that is part of the FDA-approved prescription drug labeling for certain prescription drugs when the FDA determines that: Patient labeling could help prevent. For instance, when activated, this receptor can trigger an increase in hormones called ‘incretins’, which work to:2. 5 mg dose, 2 mg/3 mL (subcutaneous solution, 1 pen) as soon as it is available for selection in the EHR, starting in March 2023. 8 mg without dose escalation, or doses of 0. Below is a text only representation of the Patient Information Leaflet (ePIL). Semaglutide is highly efficacious, with the majority of patients experiencing clinically significant weight. Semaglutide (oral): Patients start with 3 mg by mouth once daily for one month, then increase to 7 mg once daily. As experts in compounded medications, we provide custom wellness solutions to satisfy the unique needs of all types of patients. Includes patient information for visually impaired in alternative formats. Ours is a case of drug-associated acute. This will allow quick identification of new safety information. Revised: 01/2020 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. Ozempic can be used on its own in patients who cannot take metformin (another diabetes medicine). Warnings and Precautions. Experience with the use. The most common side-effects are nausea and diarrhoea - these usually reduce over time. Additionally, when providing patients with details of the vaccine or biological medicine administered, it is good practice to give them details of the brand and batch number. This means that it binds to the GLP-1 receptor in the brain and increases its activity, which has a number of favourable downstream effects. This will allow quick identification of new safety information. Important Safety Information for SEMGLEE (insulin glargine-yfgn injection) pen. Semaglutide was superior compared with liraglutide and placebo with regard to change in body weight at 26 weeks, with a reduction of 4. Healthcare Professionals (SmPC) Patient Leaflet (PIL) Letters to HCPs HCP Med Info. Semaglutide (Wegovy, Ozempic, Rybelsus) is a medicine used for weight loss in specific patients, and to lower blood sugar levels and reduce the risk of major. Semaglutide is a glucagon-like peptide-1 (GLP-1. In rodents, semaglutide causes thyroid C-cell tumors. For more information, see Section . The MHRA added that Ozempic is a “black triangle medicine”, meaning that, as a new drug, it is more closely monitored and, consequently, all suspected adverse reactions, even those from the. (). 1). Counsel patients regarding the potential risk of MTC and symptoms of thyroid Wegovy is available as pre-filled pens containing a solution for injection. 1%, the highest doses of subcutaneous semaglutide (1. 7 mg and 2. Saxenda® is used in weight loss, in addition to diet and exercise in adultsAdults and children 12 years of age and older—At first, 0. • Pancreatitis: In clinical trials, there were more cases of pancreatitis among Victoza-treated patients than among comparator-treated patients. 4 mg. Revised: 01/2023 FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: RISK OF THYROID C−CELL TUMORS 1 13INDICATIONS AND USAGE 2 DOSAGE AND. After getting a doctor's prescription, semaglutide patients are tasked with injecting themselves with the drug at home on a weekly basis. Wegovy ® (semaglutide) injection 2. 1. 25 mg, 0. This will allow quick identification of new safety information. The product code (s) for this leaflet is: 44490/0003. In rodents, semaglutide causes thyroid C-cell tumors. 4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in: adults with an initial body mass index (BMI) of ≥30 kg/m 2 (obesity) or ≥27 kg/m 2 (overweight) in the presence of at least one weight-related comorbid. Please see Important Safety Information throughout and click here for Prescribing Information and Medication Guide. The peptide has a low solubility at pH range 2-6. Semaglutide is not recommended for use in patients with end-stage renal disease. Call 1-833-275-2233 or visit RYBELSUS. In addition to. This medicine is available only with your doctor's prescription. Dulaglutide and subcutaneous semaglutide are longer-acting compounds that require once-weekly administration [22, 23]. Semaglutide is a GLP-1 receptor agonist recently approved by the FDA for weight management at a dose of 2. It may also be. The following injectable semaglutide products will be in limited supply and are unable to support uplift in demand from other GLP-1 receptor agonists: Ozempic 0. You may have heard that there are shortages of the GLP-1 analogues including Ozempic (semaglutide) and Trulicity (dulaglutide) injections. What you need to know before you use Saxenda® 3. Push and turn the needle on until it is tight. Cases of MTC in patients treated with liraglutide, another GLP-1. For further information call emc accessibility on 0800 198 5000 . Results of STEP 1-4 were published this spring: STEP 1 tested a 2. Important information If you notice severe, persistent abdominal pain, contact your GP. Your doctor may order certain tests to check your body's response to semaglutide. † Regulations require you to enter your drug identification number (DIN) to access content that is intended only for patients who have been prescribed Ozempic ® . manufacturer), and the specific batch -number. View or print the patient leaflet as PDF. the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined (5. You can help by reporting any side effects you may get. Ozempic is a prescription medicine that contains semaglutide, a substance that helps lower blood sugar levels in adults with type 2 diabetes. semaglutide, drug used in the treatment of type 2 diabetes and to aid weight loss in persons who are severely overweight. Your doctor may increase your dose every 4 weeks. Patients with Early T2D Being Treated With Diet and Exercise. It is used together with diet and exercise to help control your blood sugar. dose formulation semaglutide for treat-ment of obesity,4 thanks in part to findings from the STEP (Semaglutide Treatment Effect in People) trials of people with obesity. To reduce the risk of symptoms affecting the gut, the weekly dose is gradually increased over 16 weeks. SGLT2 inhibitors can, in rare cases lead to a. What does this medication do? Semaglutide works in the same way as a hormone produced in the gut by increasing the amount of insulin that the pancreas releases in response to food. semaglutide This medicine is subject to additional monitoring. Descriptions. For 3 mg dose, pay as little as $10 each month. The clinical evidence also suggests that Semaglutide may also help obese patients with weight loss, leaving the patient feeling more satisfied after eating. 7% in the cases 3, 2, and 1, respectively (shown in Table Table2). WEGOVY (semaglutide) injec HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY safely and. Added INS186W. 101-2476 Argentia Road. Rybelsus is effective at controlling blood glucose levels in patients with type 2 diabetes and can also help patients reduce their weight. These are not all the possible side effects of. You can help by reporting any side effects you may get. This will allow quick identification of new safety information. Rybelsus® is used to treat adults (aged 18 years and older) with type. Ozempic ® (semaglutide) injection 0. The complete list of side effects is available in the patient information leaflet, which you should read before you start to take Semaglutide. 5 mg, 1 mg, 1. Limitations of Use. Semaglutide injection Limited availability. Semaglutide (injectable): Patients start with 0. Semaglutide is a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) indicated for type 2 diabetes (T2D) and now approved by the US Food and Drug Administration for weight management in people with overweight or obesity at a once‐weekly subcutaneous dose of 2. Patients with. The typical dose for weight loss is 2. Experience with the use of semaglutide in patients with severe hepatic impairment is limited. This website provides reliable, evidence-based, and accurate information about use of medicines in pregnancy, in the form of freely available patient information leaflets called 'Bumps' ('Best Use. The clinical evidence also suggests that Semaglutide may also help obese patients with weight loss, leaving the patient feeling more satisfied after eating. An increase in demand for the medicine has led to a shortage which is currently ongoing (for. Semaglutide 7/8 Healthcare Professionals (SmPC) Patient Leaflet (PIL) Letters to HCPs. Attach a new needle. It is used together with diet and exercise to help control your blood sugar. This Patient Information has been approved by the U. Nausea occurred in 15%, diarrhoea in 10%, and vomiting in 7% of patients when treated with semaglutide. It is similar to a natural hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal. 5 mg, 1 mg, or 2 mg is an injectable prescription medicine used: along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes. Waiting less than 30 minutes or taking with food, beverages (other than plain water), or other oral medications will lessen the effect of RYBELSUS ® by decreasing absorption. It stimulates glucose-dependent. 1) and Nonclinical Toxicology (13. 8 and 4. Text HELP to 21848 for help. BAD Video Library. Alternatively telephone the hospital Diabetes nurses on 01305 255342 (available 09:00 to 16:00, seven days a week). Ozempic contains the active substance semaglutide. RYBELSUS ® (semaglutide) tablets 7 mg or 14 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. (semaglutide tablets) Product Monograph Page 1 of 39 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION RYBELSUS® semaglutide tablets 3 mg, 7 mg and 14 mg tablets ATC code: A10BJ06 Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Novo Nordisk Canada Inc. Side effects. Question Is treatment with semaglutide associated with weight loss outcomes similar to those seen in results of randomized clinical trials?. 05 L/h. This information is for use by healthcare professionals. The kit provides answers to questions about starting Ozempic ® and pen use, plus information on diet and exercise. 5 mg, 1 mg, 1. 9–16. Consumer Medicine Information (CMI) This leaflet provides important information about using Ozempic. Wegovy™ (semaglutide) injection 2. c. DOI: 10. For instance, when activated, this receptor can trigger an increase in hormones called ‘incretins’, which work to: 2. In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2. 3). How do I take this medication? Ozempic ® (semaglutide) injection 0. Revised: 01/2020 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. Consult the Patient Information Leaflet for a comprehensive list of ingredients. 3). Improvement of proteinuria was observed in the 3 patients. See the end of section 4 for how to report side effects. Serious and life-threatening cases of diabetic ketoacidosis have been reported in patients with type 2 diabetes mellitus on a combination of insulin and the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide, liraglutide. Ozempic ® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with known hypersensitivity to semaglutide or to any of the product components. The product code (s) for this leaflet is: PLGB 04668/0333. 4 mg once weekly in patients with a BMI of ≥30 kg/m 2 or ≥27 kg/m 2 with more than one weight-related comorbidity. Indication. • remind patients to read the Patient Information Leaflet (PIL) and to be vigilant for any adverse reactions, seeking medical advice when requiredSemaglutide is a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) indicated for type 2 diabetes (T2D) and now approved by the US Food and Drug Administration for weight management in people with overweight or obesity at a once‐weekly subcutaneous dose of 2. 5 mg subcutaneously once a week. Find out how dapagliflozin treats type 2 diabetes, heart failure and chronic kidney disease, and how to take it. The GLP-1 RAs available on the Pharmaceutical Benefits Scheme (PBS) come in multiple forms, including semaglutide and dulaglutide,. Always replace it to protect the medication from light. It helps your body reduce your blood sugar level only when blood sugar is too high and can help prevent heart disease. For further information call emc accessibility on 0800 198 5000. Until more information is available regarding cardiovascular outcomes, oral semaglutide is not recommended as a second-line option for those with established CV disease. Package leaflet: Information for the patient. The results obtained herein, including those of mouse and cellular models, may support further investigation into semaglutide use in patients with epilepsy and associated comorbidities. Blood and urine tests may be needed to check for unwanted effects. 2 months before a planned pregnancy due to the long washout period for semaglutide (8. Adults with an average starting A1C of 8. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Revised: 01/2020 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. Below is a text only representation of the Patient Information Leaflet (ePIL). Wegovy (Semaglutide) through. PATIENT MEDICATION INFORMATION PrWegovy™ semaglutide injection . From HRT to peptide therapies, our individualized treatments not only yield better health results – but maintain them for years to come. Drug Mar. 9 mg in PIONEER 9; once‐weekly subcutaneous dulaglutide 0. 1. advise patients on how to identify falsified packs (based on the patient information leaflet and the pictures published by the German medicines agency. 1 Pharmacodynamic Properties and 5. Changes in metabolic parameters after the start of oral semaglutide in patients who switched from GLP-1 analogues are shown in Table 4. If additional glycemic control is needed after at least 4. Recommendation: GREEN (restricted) as an alternative GLP-1 receptor agonist for patients who are unable to use subcutaneous formulations or patients who prefer oral administration. How do GLP-1 analogues work? This type of medication works by increasing the levels of a group of hormones called incretins. The authors analyzed published aggregate data and concluded that OW semaglutide 1 mg was significantly more effective than empagliflozin, dapagliflozin, and. For patients considered overweight or with obesity, we treat with semaglutide injections at the maximum dose (2. 5mg solution for injection in pre-filled penSemaglutide injection (Ozempic) is also used to reduce the risk of a stroke, heart attack, or death in adults who have type 2 diabetes along with heart and blood vessel disease. At week 30, the primary efficacy endpoint HbA1C was missing for 10%, 7% and 7% of patients and during the trial, rescue medication. Patients received weekly-once s. Risk of Thyroid C-cell Tumors. wegovy works by acting on receptors in the brain that control your appetite, causing you to feel fuller and less hungry and experience less craving for food. 4. The recommended maintenance dosage of Wegovy is 2. Dosage Form Solution for injection in pre-filled pen. It is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood) or diabetic. In the SUSTAIN 1 trial, 388 previously untreated patients were randomised to receive semaglutide (0. The product code (s) for this leaflet is: PLGB 13832/0042. Active ingredient(s): semaglutide. Maximum savings is $150 for a 1-month supply, $300 for a 2-month supply, and $450 for 3-month supply. full CMI on the next page has more details. It is a medicine that is used to lower blood sugar levels. 5 mg or 1 mg) or a placebo. 4 mg is an injectable prescription medicine that may help adults and children aged ≥12 years with obesity (BMI ≥30 for adults, BMI ≥ 95th percentile for age and sex for children), or some adults with excess weight (BMI ≥27) (overweight) who also have weight-related medical. info Ozempic ® (semaglutide) injection 0. Patient Information Leaflets. In trials of patients with early T2D insufficiently controlled with diet and exercise alone, who had baseline HbA 1c levels of 8. 00 pm on weekdays and bank holidays For more information on diabetes, visit our website If you are feeling unwell or in case of an emergency, please contact your doctor. 3 7. Changes to the PIL after your medicine was packed may mean that the version on. You can help by reporting any side effects you may get. With an elimination half-life of approximately 1. Caution should be exercised when using semaglutide in patients with diabetic retinopathy. Includes indications, proper use, special instructions, precautions, and possible side effects. Semaglutide mimics the hormone glucagon-like peptide-1 (GLP-1), which is naturally released in your gut after you eat. semaglutide. Ozempic® (semaglutide) This booklet does not replace the advice of your Healthcare professional. Findings In this cohort study of 175 patients with overweight or obesity, the total body weight loss percentages achieved were 5. Message frequency will be based on your selections. Gently pull the syringe out of the skin. Semaglutide (Ozempic®) is to be injected into the abdomen, thigh or upper arm.